Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.

Br J Cancer · 2024 · PMC10781967 · PMID 37951974

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

Among patients aged >80 years with nmCRPC, there was a notable trend toward longer maintenance of HRQoL with apalutamide plus ADT versus ADT alone.

also in 1,536 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.